Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing

Cell and gene therapies are finally becoming viable patient treatment options, with both T cell- and hematopoietic stem cell (HSC)-based therapies being approved to market in Europe. However, these therapies, which involve the use of viral vector to modify the target cells, are expensive and there i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hum Gene Ther
Autori principali: Radek, Constanze, Bernadin, Ornellie, Drechsel, Katharina, Cordes, Nicole, Pfeifer, Rita, Sträßer, Pia, Mormin, Mirella, Gutierrez-Guerrero, Alejandra, Cosset, François-loïc, Kaiser, Andrew D., Schaser, Thomas, Galy, Anne, Verhoeyen, Els, Johnston, Ian C.D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Mary Ann Liebert, Inc., publishers 2019
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6919281/
https://ncbi.nlm.nih.gov/pubmed/31578886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2019.157
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi